Veterinary Biologics Market Report 2025

The veterinary biologics market size has grown strongly in recent years. It will grow from $12.67 billion in 2024 to $13.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to animal disease outbreaks, regulatory support and standards, demand for food safety, globalization of trade, and economic significance of livestock.

The veterinary biologics market size is expected to see strong growth in the next few years. It will grow to $18.38 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to emerging infectious diseases, climate change and disease patterns, precision livestock farming, one health approach, and increased pet ownership trends. Major trends in the forecast period include education and training programs, eco-friendly and sustainable biologics, integration of digital health records, rise in companion animal biologics, and customized and targeted therapies.

The upsurge in the prevalence of animal diseases is anticipated to be a driving force behind the growth of the veterinary biologics market. Animal diseases encompass a range of illnesses affecting diverse animal species. The escalation in these diseases underscores the need for advanced diagnostic and treatment solutions, a demand met by veterinary biologics that employ immunological methods to address and manage animal diseases. As of October 2022, the European Center for Disease Prevention and Control reported 2,467 outbreaks of avian influenza in poultry, impacting 48 million birds, with an additional 187 cases observed in captive birds. In a related context, the World Health Organization disclosed in July 2022 that rabies claims the lives of 59,000 people annually across over 150 countries, with a predominant 95% of cases concentrated in Africa and Asia. This surge in animal diseases is a pivotal factor propelling the veterinary biologics market.

The increasing trend of pet adoption is poised to contribute significantly to the growth of the veterinary biologics market. Pet adoption involves assuming responsibility for a domesticated animal, often from shelters or rescue organizations, to provide a permanent and caring home. Veterinary biologics play a crucial role in preventing infectious diseases in pets, offering immunity, controlling zoonotic diseases, enhancing lifespan and quality of life, reducing veterinary healthcare costs, improving reproductive health in pets, and providing more targeted and customized treatment options. Data from October 2023, as reported by the American Pet Products Association, reveals that 66% of U.S. households, totaling 86.9 million, own a pet - an increase from 62% in 2022. This surge in pet adoption is a significant driver behind the expanding veterinary biologics market.

Leading companies in the veterinary biologics market are concentrating on the development of innovative biologics, such as vaccines, to improve animal health and prevent diseases. A vaccine is a substance that triggers the immune system to recognize and combat specific pathogens, helping to prevent infectious diseases by providing acquired immunity. For example, in August 2024, Merck Animal Health, a global animal health company based in the U.S., launched an experimental autogenous vaccine targeting avian metapneumovirus (aMPV) type B, which received approval from the U.S. Department of Agriculture (USDA) for manufacturing and sale. Created in partnership with Cambridge Technologies, this vaccine aims to address the serious respiratory problems caused by aMPV type B in poultry, which have resulted in significant economic losses since late 2023. Manufactured at a state-of-the-art facility in Minnesota, the vaccine uses an oil and water emulsion formulation designed to reduce post-vaccination tissue reactions, filling a crucial gap in the market as there were previously no commercially licensed vaccines available.

Companies at the forefront of the veterinary biologics market are also channeling their efforts into the creation of innovative products, such as injections designed to control pain associated with osteoarthritis (OA) in dogs. These injections target canine nerve growth factors, providing an effective means to alleviate the pain that dogs experience due to osteoarthritis. Zoetis Inc., a distinguished U.S.-based animal health company, secured approval from the U.S. Food and Drug Administration (FDA) for Librela (bedinvetmab injection) in May 2023. Positioned as the first and only monthly anti-NGF monoclonal antibody medication for canine OA pain, Librela stands out as a safe and efficacious solution for managing long-term OA pain symptoms in dogs. This approval underscores Librela's role in enhancing the mobility and overall well-being of canines grappling with osteoarthritis, contributing to an improved quality of life for these animals.

In January 2024, Ceva Santé Animale, a pharmaceutical company based in France, acquired Scout Bio for an undisclosed amount. This acquisition enhances Ceva's biotechnology capabilities and speeds up its innovation in pet therapeutics, particularly targeting advanced treatments for chronic diseases. This strategic move responds to the growing demand for better health solutions among pet owners. Scout Bio is a biotechnology company located in the U.S. that specializes in providing essential data for the development of effective veterinary biologics, including vaccines and diagnostics.

Major companies operating in the veterinary biologics market include Bayer AG, Eli Lilly & Company, Evonik Industries AG, Zoetis Inc., Merck Animal Health Inc., Boehringer Ingelheim Animal Health Inc., Elanco Animal Health, IDEXX Laboratories Inc., Virbac SA, Phibro Animal Health Corporation, Vetoquinol, Abaxis Inc., Bimeda Biologicals, Ceva Sante Animale S.A., Heska Corporation, Colorado Serum Company, Hester Biosciences Limited, INDICAL Bioscience GmbH, Ambrx Biopharma Inc., Adamis Pharmaceuticals Corporation, Intervet Inc., Hebei Veyong Animal Pharmaceutical Co. Ltd., FidoCure, Biomet Biologics LLC, CytoDyn Veterinary Medicine LLC, KM Biologics.

North America was the largest region in the veterinary biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the veterinary biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the veterinary biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Veterinary biologics encompass biological products obtained from living organisms such as viruses, bacteria, or other microorganisms. These specialized products in veterinary medicine serve to prevent, diagnose, or treat diseases in animals.

Key products falling under veterinary biologics include vaccines, diagnostic kits, immunomodulators, antiserums, antibodies, and related items. Vaccines, for instance, are formulated to trigger the immune system's response and offer protection against specific animal diseases. They address various ailments such as bluetongue, foot and mouth disease, brucellosis, tuberculosis, and others. These products are distributed through multiple channels, including veterinary hospitals and clinics, for diverse applications involving both production and companion animals.

The veterinary biologics market research report is one of a series of new reports that provides veterinary biologics market statistics, including veterinary biologics industry global market size, regional shares, competitors with a veterinary biologics market share, detailed veterinary biologics market segments, market trends and opportunities, and any further data you may need to thrive in the veterinary biologics industry. This veterinary biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The veterinary biologics market consists of sales of transplant tissues, recombinant proteins, and stem cells. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.